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AObjectives: Controversy about quality-of-life (QOL) benefits of sen-
tinel lymph node biopsy (SLNB) versus axillary lymph node dissec-
tion (ALND) in patients with breast cancer remains. Our aim was to
compare the impact of SLNB and ALND on QOL and arm symptoms of
patients with early breast cancer, using generic (short form 36
health survey) and tumor site–specific (FACT-B4) instruments.
Methods: This was a prospective longitudinal observational study of
93 patients (64 SLNB, 29 ALND). Patients were evaluated presurgery
and 1, 6, and 12 months postsurgery. Generalized estimation equa-
tion models were constructed to assess the effect of treatment on
QOL. The relative risks of edema, dysesthesia, and heaviness were
calculated comparing ALND to SLND. Results: Most patients pre-
sented T1 (67.7%) and underwent breast-conserving surgery (92.5%).
At 12 months, the SLNB group presented deterioration on the FACT-
B4 Arm Scale (beta coefficient estimated a change of 1.6 score
ina
celon
al So
ttp://dx.doi.org/10.1016/j.jval.2012.06.003oints; P 0.01) while, compared with SLNB, the deterioration in the
LND group was almost 2 additional score points higher (P  0.009).
FACT-B4 global summary and short form 36 health survey did not
show statistically significant differences between groups. Relative
risk of dysesthesia and subjective edema was higher for the ALND
group than for the SLNB group (1.97 and 2.11 at month 12; P  0.01).
Conclusion: These results confirm the benefit of SLNB due to its
lower arm morbidity impact on QOL, compared with ALND. There
are clinically relevant between-treatment differences in the Arm
Scale of FACT-B4, while there were no relevant differences in gen-
eral well-being, measured with the disease-specific FACT-B4 and
the generic short form 36 health survey.
Keywords: breast cancer, health-related quality of life.
Copyright © 2012, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Breast cancer is the most prevalent cancer among women in de-
veloped countries. In Spain, the incidence is 81.1 new cases a year
per 100,000 women, the 5-year survival is 82%, and consequently
the prevalence of women who have undergone breast cancer is
very high [1,2]. This means that minimizing the morbidity associ-
ated with breast cancer treatments andmaintaining quality of life
(QOL) are priority goals.
The clinical stage plays a central role in the breast cancer sur-
gical approach. Breast-conserving surgery is considered the stan-
dard option in early stages [3], and full dose of radiotherapy must
be delivered usually after. Breast-conserving surgery provides a
better body image than mastectomy initially after surgery [4]. The
mastectomy approachmust be chosenwhen there is a high risk of
local recurrence. Large tumors in a small breast, persistent posi-
tive margins after resection, diffuse calcifications, predictable
poor cosmetic outcome, and contraindications to radiation ther-
* Address correspondence to: Roser Belmonte, Department Medic
ospital Mar-Esperança, C/St. Josep de la Muntanya, 12, 08028 Bar
E-mail: rbelmonte@parcdesalutmar.cat.
098-3015/$36.00 – see front matter Copyright © 2012, Internation
ublished by Elsevier Inc.apy are breast-conserving contraindications. Finally, women with
early stage breast cancer may opt for mastectomy because of per-
sonal preference.
Lymph node spread is an important prognostic factor in
breast cancer. In early stage tumors, with clinically and ultra-
sound negative involvement of the axilla, node spread can be
determined by the technique of selective sentinel lymph node
biopsy (SLNB). The American Society of Clinical Oncology in
2005 [5], and more recently the British Association of Surgical
Oncology [6], endorsed SLNB as the recommended method of
staging early breast cancer in clinically node negative patients
because of its benefits compared with axillary dissection on arm
morbidity. When sentinel nodes are tumor free, axillary lymph
node dissection (ALND) is considered unnecessary [7], and so
SLNB enables a large number of patients to save their axillary
nodes and, consequently, avoid the potential side effects of ax-
illary clearance [8–12]. Despite the extension of this conserva-
tive method, ALND remains a necessary technique in node-pos-
Física i Rehabilitació, Hospital Mar-Esperança Parc de Salut Mar,
a, Spain.
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number of patients.
Several studies comparing both surgical procedures, SLNB
and ALND, showed that SLNB is associated with shorter hospital
stay, earlier return to normal activity, and lower rates of short-
and long-term morbidities, such as infection, seroma, shoulder
movement impairment [11–15], neuropathy, and upper limb
lymphedema [16–18].
However, QOL benefits of SLNB are not as clearly demonstrated.
Most studies presented somemethodological problems, such as the
absence of pretreatment assessment and reliable and validated QOL
instruments.Kootstra et al. [19], focusingonpublishedwell-designed
prospective studies (observational or randomized clinical trials),
pointed out that there were no differences in QOL between women
treatedwithSLNBorALND.TheAxillaryLymphaticMappingAgainst
Nodal Axillary Clearance (ALMANAC) trial was the only exception to
this pattern, showing better QOL among women of the SNLB group
[20]. This striking discrepancy has been explained by suggesting cer-
Table 1 – Patient characteristics.
All
(n  93)
Age (y), mean  SD 59.2  8.6
Body mass index (kg/m2) 32.1 (24.6)
Affected side
Dominant 51 (58.0%)
Nondominant 37 (42.0%)
Surgery technique
Breast conserving 86 (92.5%)
Mastectomy 7 (7.5%)
T (tumor size category)
IS 9 (9.7%)
1 63 (67.7%)
2 20 (21.5%)
3 1 (1.1%)
N (node involvement)
0 68 (73.1%)
1 22 (23.7%)
2–3 3 (2.2%)
Tumor size (mm) 13.9 (7.4)
Number of lymph nodes removed, mean  SD 6.1  7.4
Histology
Ductal carcinoma 82 (88.2%)
Lobular carcinoma 11 (11.8%)
Multiple primary neoplasm
No 81 (87.1%)
Yes 12 (12.9%)
Differentiation
I 27 (32.9%)
II 32 (39.0%)
III 23 (28.0%)
Radiotherapy 84 (90.3%)
Chemotherapy 47 (50.5%)
Hormonotherapy 70 (75.3%)
Education
Primary 61 (69.3%)
Secondary and university 27 (30.7%)
Work
Employed 34 (38.6%)
Unemployed 4 (4.5%)
Housewife 31 (35.2%)
Permanently incapacitated 2 (2.3%)
Retired 17 (19.3%)
ALND, axillary lymph node dissection; SLNB, sentinel lymph node bitain limitations in the questionnaires to cover all relevant aspects inthis area [21,22]. All the above studies used generic QOL instruments
suchas short form36health survey (SF-36) or EuropeanOrganization
for Research and Treatment of Cancer Quality of Life Questionnaire
(EORTC-QLQ-C30), whereas the ALMANAC trial was the only one us-
ing the FACT-B4, a tumor site–specific instrument.
The main objective of this study was to compare the impact of
SLNB andALNDon theQOL of patientswith early breast cancer during
the first year after surgery using both generic (SF-36) and tumor site–
specific (FACT-B4) instruments that assess upper limb impairment.
Methods
This was a prospective longitudinal observational study of inci-
dent breast cancer patientswith surgery as first treatment. Autho-
rization was obtained from the Ethics Committee on Medical Re-
search, and all participants gave their written informed consent.
Consecutive patients of all ages were recruited from the sur-
SLNB
(n  64)
ALND
(n  29)
P
59.8  8.8 57.9  8.0 0.320
32.7 (29.6) 30.7 (5.3) 0.711
34 (56.7%) 17 (60.7%) 0.720
26 (43.3%) 11 (39.3%)
64 (100.0%) 22 (75.9%) 0.001
0 (0.0%) 7 (24.1%)
9 (14.1%) 0 (0.0%) 0.001
48 (75.0%) 15 (51.7%)
7 (10.9%) 13 (44.8%)
0 (0.0%) 1 (3.4%)
64 (100.0%) 4 (13.8%) 0.001
0 (0.0%) 22 (75.9%)
0 (0.0%) 3 (10.3%)
12.6 (6.1) 18.1 (9.4) 0.009
1.6  0.8 16.0  5.1 0.001
58 (90.6%) 24 (82.8%) 0.277
6 (9.4%) 5 (17.2%)
58 (90.6%) 23 (79.3%) 0.132
6 (9.4%) 6 (20.7%)
23 (39.7%) 4 (16.7%) 0.128
20 (34.5%) 12 (50.0%)
15 (25.9%) 8 (33.3%)
58 (90.6%) 26 (89.7%) 0.883
21 (32.8%) 26 (89.7%) 0.001
48 (75.0%) 22 (75.9%) 0.929
42 (71.2%) 19 (65.5%) 0.588
17 (28.8%) 10 (34.5%)
25 (42.4%) 9 (31.0%) 0.689
3 (5.1%) 1 (3.4%)
18 (30.5%) 13 (44.8%)
1 (1.7%) 1 (3.4%)
12 (20.3%) 5 (17.2%)gery department of a general university hospital with a commu-
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were having an invasive carcinoma or high-grade ductal carci-
noma “in-situ” of the breast, and to be considered for surgery as
the first choice treatment. Exclusion criteria were preexisting se-
vere disorders on the upper limb of the side involved (i.e., nerve
damage, amputations. . .), or cognitive impairment, which could
make collaboration difficult.
Treatment
The patients underwent breast-conserving surgery or mastec-
tomy with SLNB when sentinel node was negative or with level
II ALND when the presurgical, perioperative, or definitive sen-
tinel node study was metastatic. SLNB was conducted as de-
scribed elsewhere [23]. SLNB indications, adjuvant systemic
hemotherapy, hormonal treatment, and/or locoregional radio-
herapy were applied according to the national oncological
uidelines and the most recent national and international con-
ensus [5,24,25].
Data collection and follow-up
Sociodemographic information was self-reported at baseline, and
the tumor clinical characteristics were collected from medical re-
cords (type, grade and stage of tumor, surgical and adjuvant treat-
ments applied, and number of lymph nodes removed).
Clinical assessment took place in the rehabilitation setting of
the breast cancer unit, before surgery and at months 1, 6, and 12
Table 2 – Repeated-measures analysis of variance of qualit
n Mean  SD
Pretreatment Month 1 Month
SLNB group 51
FACT-B4
Physical 50 25.03  3.13 23.09  5.84 22.06  4
Social 48 22.76  4.31 23.14  3.69 21.63  4
Emotional 49 14.29  4.47 15.69  4.37 15.69  4
Functional 49 18.84  4.72 17.94  5.27 17.38  4
Breast 49 22.21  5.22 20.57  4.69 21.45  5
Arm 49 19.27  1.93 17.96  2.86 17.31  4
TOI 48 85.20  11.02 79.73  13.12 77.84  1
FACT-B4
global
summary
47 122.25  15.78 118.62  16.77 115.10  2
SF-36
PCS 48 50.83  8.79 42.68  8.79 42.76  9
MCS 48 46.65  13.09 47.41  12.01 46.75  1
ALND Group 21
FACT-B4
Physical 20 25.12  2.90 21.94  4.42 22.00  4
Social 20 23.71  3.72 24.53  3.42 22.62  5
Emotional 20 12.67  5.28 14.99  4.81 14.92  4
Functional 19 18.47  4.67 17.72  5.79 18.16  6
Breast 18 19.90  5.02 20.57  4.40 20.95  5
Arm 19 19.32  1.86 14.89  4.20 16.37  2
TOI 17 81.96  10.72 75.10  12.25 76.95  1
FACT-B4
global
summary
17 117.79  17.58 113.91  17.28 113.63  2
SF-36
PCS 18 51.36  8.05 42.99  8.69 44.32  8
MCS 18 43.50  12.20 45.35  9.79 46.00  1
ALND, axillary lymphnode dissection; ANOVA, analysis of variance;M
form 36 health survey; SLNB, sentinel lymph node biopsy; TOI, Trial
* Bonferroni adjustment for multiple comparisons.postsurgery. Self-reported symptoms included the presence or ab-sence of paresthesia, heaviness, and edema. The clinical exami-
nation included the detection of neurological disorders, winged
scapula, the shoulder range ofmotion (flexion, abduction, external
rotation, and internal rotation) as measured by a goniometer in
degrees, and the volume of both upper limbs obtained bymeasur-
ing six circumferences and applying the truncated cone formula
[26]. The affected arm volume change over time was calculated by
subtracting the volume at baseline from the volume at follow-up.
Furthermore, the affected arm volume change was corrected by
subtracting the unaffected arm volume changes. This correction
allows controlling the possible variation caused by body composi-
tion changes (e.g., gains or losses in weight).
Quality-of-life questionnaires
QOL was assessed before surgery and at months 1, 6, and 12 post-
surgery. Generic and breast cancer–specific questionnaires were
self-administered at the waiting room before the clinical assess-
ment. The SF-36 version 2 [27] was used. Scores for the two sum-
mary components (Physical Component Scale [PCS] and Mental
Component Scale [MCS]) were calculated by using the recom-
mended standardized procedure where scores higher or lower
than 50 indicate better or worse QOL, respectively, than the gen-
eral US population [28,29].
The FACT-B4 is a QOL questionnaire [30,31] composed of 40
items covering four generic scales of well-being (Physical, Emo-
tional, Social, and Functional) and two side-specific scales: Breast
-life measures.
P (ANOVA) P (vs. pretreatment)*
Month 12 Month 1 Month 6 Month 12
23.27  4.43 0.002 0.102 0.001 0.092
21.47  4.35 0.070 – – –
16.81  4.13 0.001 0.098 0.109 0.002
18.21  5.14 0.226 – – –
22.27  5.19 0.108 – – –
17.66  3.33 0.003 0.027 0.032 0.027
80.89  14.32 0.023 0.023 0.007 0.216
119.05  19.47 0.085 – – –
44.65  9.22 0.001 0.001 0.001 0.001
47.52  12.43 0.941 – – –
21.70  3.74 0.062 – – –
22.08  4.42 0.119 – – –
15.70  4.19 0.004 0.204 0.071 0.012
18.37  5.59 0.691 – – –
20.25  5.08 0.559 – – –
15.16  2.93 0.001 0.003 0.002 0.001
75.15  11.59 0.118 – – –
111.89  15.88 0.415 – – –
43.49  9.24 0.023 0.045 0.036 0.007
46.15  11.68 0.606 – – –
ental Component Scale; PCS, Physical Component Scale; SF-36, short
me Index.y-of
6
.53
.78
.23
.69
.37
.38
5.74
1.75
.46
1.61
.50
.14
.96
.47
.20
.59
4.92
2.15
.48
3.73
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i
b
s
a
p
g
t
i
a
p
e
t
c
t
c
A
t
p
h
g
w
e
t
m
g
t
c
N
t
i
910 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 9 0 7 – 9 1 5version administered showed adequate psychometric properties
comparable to those of the original version [32]. Patients indicated
to what degree each item statement has applied over the past 7
days in a Likert five-point response option scale ranging from 0
(not at all) to 4 (very much). Two summary scores were obtained:
the Trial Outcome Index (TOI) and the FACT-B4. TOI is obtained
by the sum of Physical and Functional well-being scores plus the
Breast Cancer andArm scales scores (range 0–108 points), and The
FACT-B4 is obtained by adding the scores of all the 40 items of
the questionnaire (range 0–160). The TOI has been recommended
[30] for clinical trials as a precise summary measure because it
showed ahigh reliability and sensitivity. Using TOI allows enhanc-
ing measurement sensitivity and reduces outputs, summarizing
physical and functional outcomes. TOI is considered an estab-
lished targeted index [20,33]. Eton et al. [34] estimated theminimal
mportant difference of TOI as 5 to 6 points. Higher scores indicate
etter QOL.
Analysis
A total of 110 patients (one third with ALND) were considered
necessary to detect a difference between SLNB and ALND groups
of 1.3 points (SD  2) in the Arm Scale of FACT-B4 [20] with a
tatistical power of at least 80% at a significance level of 5%, with
n expected loss to follow-up of 20%, which corresponds to 88
atients at month 12.
Patient characteristics and clinical outcomes of the study
roups (SLNB and ALND) were compared by using 2 or unpaired t
Table 3 – Clinical findings and shoulder movement reducti
surgery.
Experienced symptoms during year
Presence of subjective edema
1 mo
6 mo
12 mo
Dysesthesia
1 mo
6 mo
12 mo
Heaviness
1 mo
6 mo
12 mo
M
Arm volume change corrected for
contralateral change (mL)§
1 mo 1
6 mo 2
12 mo 
Reductions in range of shoulder
movement (in degrees) at 12 mo§
Flexion
Abduction
Internal rotation
External rotation
ALND, axillary lymph node dissection; CI, confidence interval; SE, sta
* Chi-square tests.
† Relative risk (RR) was calculated considering the SLNB group as ref
‡ Unpaired t test.
§ Compared with preoperative values.ests depending on the nature of the variables. Intragroup changes pn QOL were assessed by using univariate repeated-measures
nalysis of variance. When change was statistically significant,
airwise comparisons between the pretreatment evaluation and
ach posttreatment evaluation were made by using the paired t
est with Bonferroni’s method to adjust for multiple comparisons.
The objective assessment of arm swelling was expressed as
hanges in affected armvolume over time corrected for changes in
he unaffected arm, for each patient at each time point. The 95%
onfidence interval of the mean difference between SLNB and
LND groups was calculated for the arm volume change and for
he reductions in shoulder movement. The relative risk for the
resence of subjective edema and clinical findings (dysesthesia,
eaviness, winged scapula) was calculated considering the SLNB
roup as reference (relative risk  1).
Figures showing the evolution of QOL scores during follow-up
ere constructed for each treatment group. To examine the effect of
ducation, figures showing the evolution of QOL scores according to
he level of education were also constructed. The differences in QOL
ean scores at each assessment were compared between study
roups by using the unpaired t test. Generalized estimating equation
modelswere constructedwith theArmScale, theTOI, and the FACT-
B4 global summary as dependent variables to assess the effect of
reatment (SLNB vs. ALND) on QOL over time, while accounting for
orrelation among repeatedmeasures. Age, bodymass index, T and
cancer staging, radiotherapy, chemotherapy, and hormono-
herapy were included in the models as adjusting factors. Time was
ncluded in themodel as a categorical variablewith four categories—
in the SLNB and ALND groups during the 12 mo after
B ALND P* RR (95% CI)†
24.1% 0.032 1.74 (0.88–3.45)
31.0% 0.004 2.35 (1.03–5.37)
35.5% 0.002 2.11 (1.09–4.06)
75.9% 0.001 1.81 (1.29–2.53)
65.5% 0.048 1.37 (1.00–1.87)
69.2% 0.001 1.97 (1.28–3.04)
17.2% 0.048 1.91 (0.77–4.71)
24.1% 0.056 1.68 (0.84–3.33)
15.4% 0.471 1.22 (0.66–2.23)
B
(SE)
ALND
Mean (SE)
P‡ Mean difference
(95% CI)
9,3) 33.3 (22.8) 0.183 44.5 (21.4 to 110.3)
6.2) 109.5 (34.7) 0.001 134.9 (212.5 to 57.4)
4.5) 96.7 (51.1) 0.062 103.5 (212.5 to 5.5)
.3) 5.7 (1.5) 0.170 3.1 (7.5 to 1.4)
.3) 7.4 (2.6) 0.830 0.8 (8.4 to 6.8)
.1) 3.5 (1.3) 0.229 2.2 (5.8 to 1.4)
.4) 6.3 (1.9) 0.071 4.5 (9.5 to 4.0)
d error; SLNB, sentinel lymph node biopsy.
e (RR  1).ons
SLN
7.9%
7.1%
11.8%
31.7%
42.9%
25.5%
4.8%
8.9%
9.8%
SLN
ean
1.2 (1
5.4 (1
6.8 (1
2.5 (1
6.6 (2
1.3 (1
1.8 (1
ndar
erencretreatment (reference) andmonths1, 6, and12—topreventassum-
911V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 9 0 7 – 9 1 5ing a linear association. SLNBwas used as the reference group in the
models, and interactions between treatment and time were also in-
cluded. The statistical analyses were carried out by using SPSS 12.0
and SAS 9.1 software.
Results
From October 2006 to February 2009, a total of 121 patients agreed
to participate. Twelve patients were excluded because of previous
neoadjuvant chemotherapy, two patients because of severe shoul-
der pain and limitation before surgery, and one because of skin
squamous cell carcinoma. Five participants refused to complete
the QOL questionnaires at baseline, and another eight refused to
continue in the study after baseline evaluation (five SLNB and
threeALND). From93 patients included in the study, 64 underwent
SLNB, 9 SLNB followed by ALND, and 20 ALND as the first proce-
dure. Therefore, the ALND group comprised 29 patients, 31.2% of
FACT-B+4 
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Fig. 1 – Mean QOL scores by trethe sample. QOL questionnaire completion rates at follow-upwere95.7% (n  89), 90.3% (n  84), and 86.0% (n  80) at 1, 6, and 12
months after surgery, respectively.
Table 1 shows the patients’ clinical and demographic charac-
teristics. There were significant differences between SLNB and
ALND in surgery technique: all patients in the SLNB group under-
went tumorectomy while seven patients in the ALND group
(24.1%) underwent mastectomy. Differences in tumor size cate-
gory, node involvement, metastasis (TNM) cancer staging were
also statistically significant: the SLNB groupwasmostly composed
of patients in T1 or carcinoma in situ (89.1%) and N0, while almost
half the patients presented T2 and 72.4% N 1 in the ALND group.
The mean number of lymph nodes removed in the ALND group
was 15.9  5.4. Most patients (90.3%) received radiotherapy and
75.3% hormonotherapy without differences between SLNB and
ALND groups, while chemotherapy was more frequent in the
ALND group (89.7% vs. 32.8%; P  0.001). The education level and
the work status did not show significant differences between
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912 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 9 0 7 – 9 1 5Table 2 shows the pre- and posttreatment QOL scores for the
SLNB and ALND groups. Among patients who underwent SLNB,
deterioration after surgerywas observed on the FACT Physical and
Arm scales and FACT TOI summary. No statistically significant
changes over timewere observed for Social, Functional, and Breast
scales of FACT-B4. Compared with the pretreatment evaluation,
the FACT Emotional Scale was significantly higher (better) at 12
months (means of 16.8 vs. 14.3; P 0.001). This general patternwas
similar for patients who underwent ALND, except for the FACT
Physical Scale and FACT TOI, which presented no statistically sig-
nificant differences among evaluations in this group. Both groups,
SLNB and ALND, showed a significant decline in SF-36 PCS score
after surgery, which persisted at 12 months of follow-up.
Table 3 shows clinical findings in the SLNB and ALND groups
during the 12 months after surgery. Subjective edema was more
common among patients treated with ALND than with SLNB at 1,
6, and 12 months of follow-up, with relative risk of 1.74, 2.35, and
2.11, respectively. Dysesthesia was significantlymore frequent for
FACT-B+4 
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Fig. 2 – Mean QOL scores by levALND than for SLNB patients at each follow-up. Measured volumeof affected upper limb increased around 100mLmore for theALND
group than for the SLNB group at 6 and 12 months. Small negative
values observed at some follow-ups could be explained in part by
physiological differences between both arms, as well as the asso-
ciated error of measurement. However, other factors could not be
excluded. There was one case of winged scapula belonging to the
ALND group. The results for shoulder mobility were expressed as
average reductions in the range ofmovements 1 year after surgery
compared with preoperative values. Reduction in mobility was
always higher on average in the ALND group, but differences be-
tween groups were not statistically significant.
Figure 1 shows the evolution of QOL during follow-up for each
treatment group. The impact of surgery on the Arm Scale was
higher among patients who underwent ALND, with the mean
scores presenting statistically significant differences between
groups at 1, 6, and 12months after surgery. Surgery impact on TOI
was higher in the short term, especially for the ALND group. Both
groups showed a similar pattern of initial deterioration and sub-
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913V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 9 0 7 – 9 1 5tween treatment groups for the physical and mental component
summaries of SF-36.
Figure 2 shows the QOL evolution according to education
level. Patients with primary studies showed poorer values in the
TOI and the FACT-B4 Global Summary at baseline, but these
differences disappeared after surgery. SF-36 showed significant
differences by education level only at 6 months in PCS and at 1
month in MCS.
Table 4 shows the results of the generalized estimation
equation models constructed to assess QOL at different fol-
low-up evaluations. In the FACT Arm model, patients in the
SLNB group showed a statistically significant deterioration
throughout follow-up compared with baseline. Beta coefficients
estimated a change of 1.15, 1.87, and 1.58 in score points at
1, 6, and 12 months (P  0.01). This deterioration was signifi-
cantly higher for the ALND group, which presented 1.96 addi-
tional points of change on FACT Arm score at month 12 (P 
.009) compared with the SLNB group. The model with the TOI
howed that patients in the SLNB group presented a statistically
ignificant deterioration throughout follow-up compared with
aseline (beta coefficients indicated 5.37, 7.62, and 4.47
oints of change at 1, 6, and 12 months, respectively; P  0.05).
he deterioration observed for the ALND group was not signif-
cantly different from that observed for the SLNB group. Simi-
arly, the PCS of SF-36 showed statistically significant deterio-
ation throughout follow-up compared with baseline. Beta
oefficients estimated a change of 7.91, 8.14, and 5.56
oints of PCS score at 1, 6, and 12 months without group differ-
nces. Finally, impairment measured with the FACT-B4 Global
ummary was statistically significant only at month 6 (7.88
Table 4 – GEE models constructed to assess the effect of SL
index, radiotherapy, chemotherapy, and hormonotherapy
FACT-B4
Arm Scale
P FACT-B4 Tria
Outcome Inde
 (SE)  (SE)
Intercept 16.20 (1.94) 0.001 85.18 (11.38)
T
IS Ref. Ref.
T0 0.27 (0.76) 0.721 3.28 (4.43)
T2–T3 0.06 (0.92) 0.950 3.05 (5.22)
N
0 Ref. Ref.
1–3 0.46 (0.95) 0.625 3.10 (4.83)
Group
SLNB Ref. Ref.
ALND 0.41 (0.88) 0.639 5.89 (5.22)
Interaction Group  Time
SLNB  Time (SLNB change
from baseline)
Basal Ref. Ref.
1 mo 1.15 (0.41) 0.005 5.37 (1.69)
6 mo 1.87 (0.64) 0.004 7.62 (2.05)
12 mo 1.58 (0.50) 0.001 4.47 (1.87)
ALND  Time (difference
between ALND and
SLNB on change)
Basal Ref. Ref.
1 mo 2.97 (0.99) 0.003 2.68 (3.43)
6 mo 1.12 (0.92) 0.226 2.70 (3.67)
12 mo 1.96 (0.75) 0.009 1.76 (2.97)
ALND axillary lymph node dissection; GEE, generalized estimation
sentinel lymph node biopsy; T, tumor size category; N, node involvemcore points; P  0.003). tDiscussion
In summary, this observational study of patients with breast cancer
has shown that relevant differences persisted between SLNB and
ALND groups for arm morbidity and its impact on functioning and
QOL throughout 1 year after treatment. However, differences be-
tween groups detected by generic measures of QOL were negligible.
Deterioration of arm functioning after surgery measured with
FACT-B4 remained in both SLNB and ALND groups throughout
the whole year of follow-up, but the deterioration was greater for
the ALND group. The magnitude or clinical importance of the dif-
ferences between SLNB andALNDgroupswas interpreted by using
the standard categorization of effect size (ES) [35], and so 0.2, 0.5,
and 0.8 of the SD represent small, moderate, and large differences,
respectively. At the end of follow-up, patients in the ALND group
scored almost 2 points lower in Arm score than did patients in the
SLNB group (beta regression coefficient  1.96; P  0.009); given
n SD of 2.0 on the Arm score at baseline, the ES was large (ES 
.98), indicating a relevant difference between SLNB and ALND.
ur findings were almost identical to those of the ALMANAC clin-
cal trial, which included the development of the new Arm sub-
cale to improve the breast cancer site-specific module, resulting
n the FACT-B4 questionnaire [20,31]. Peintinger et al. [22] also
eported similar findings with the Arm subscale of the EORTC
LQ-BR23: patients treated with ALND showed a statistically
igher deterioration (mean of change  12.9; 95% CI 6.2 to 19.6)
han did patients treated with SLNB (mean of change  5.5; 95%
I 14.1 to 3.1).
Arm functioningwas ameasure of the impact of armmorbidity
n the women’s QOL. In this sense, differences in the Arm func-
nd ALND on quality of life (adjusted by age, body mass
P FACT-B4
global summary
P SF-36 Physical
Component Summary
P
 (SE)  (SE)
.001 123.60 (14.79) 0.001 55.74 (6.40) 0.001
Ref. Ref.
.459 1.84 (5.83) 0.752 2.87 (2.59) 0.268
.559 2.50 (7.09) 0.725 1.12 (3.04) 0.712
Ref. Ref.
.522 2.94 (6.51) 0.651 3.87 (2.91) 0.184
Ref. Ref.
.259 8.70 (7.25) 0.230 1.89 (3.31) 0.568
Ref. Ref.
.001 2.97 (2.12) 0.161 7.91 (1.41) 0.001
.000 7.88 (2.66) 0.003 8.14 (1.58) 0.001
.017 3.54 (2.47) 0.152 5.56 (1.29) 0.001
Ref. Ref.
.435 2.28 (4.47) 0.609 0.02 (2.86) 0.993
.461 5.19 (4.93) 0.292 2.10 (2.47) 0.395
.554 1.34 (4.12) 0.746 1.25 (2.22) 0.572
tion; SE, standard error; SF-36, short form 36 health survey; SLNBNB a
).
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914 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 9 0 7 – 9 1 5larger volume change and the higher rate of self-reported symp-
toms (e.g., 35.5% vs. 11.8% subjective edema at 12 months; P 
0.002) among patients who underwent ALND compared with pa-
tients who underwent SLNB. Our findings agree with those re-
ported by Purushotham et al. [36] who observed that the SLNB
roup was less likely to have subjective edema (70%–80% reduc-
ion in overall odds ratios), a lower increase in measured volume,
nd less reduction of some shoulder movements.
FACT-B4 summaries showed a decline (QOL deterioration) 1
onth after surgery with a subsequent partial recovery. There
ere no significant differences in the TOI and global summary
cores of FACT-B4 (beta coefficients  1.76 and 1.34, respec-
ively, at month 12) when comparing the SLNB group with the
LND group. Reported differences between SLNB and ALND
roups in the ALMANAC trial [20] were similar, around 2 points on
OI and FACT-B4 global summaries atmonth 12, but statistically
ignificant (P  0.011 and P  0.024, respectively). Beyond statisti-
al significance, the clinical relevance of these differences is argu-
ble. These 2-point differences detected in the ALMANAC trial are
ar from the minimal important difference of 5 points previously
efined for the TOI and the FACT-B4 summaries, and they reflect
nly a small ES (0.2). This clinical relevance–based interpretation
f the differencesmake ALMANACfindings totally consistentwith
urs, and also with results from previous studies using the EORTC
LQ-C30 [19,22].
Regarding the results of the generic SF-36, compared with
panish SF-36 reference norms [29], patients presented a slight
eterioration in their MCS scores (mean  45.8; SD  12.7) but a
imilar PCS score (mean  49.5; SD  9.4) before surgery. The me-
ian of the SF-36 MCS and PCS scores are 50.1 and 47.5 in 55- to
4-year-old Spanish women [27]. The mental component was
uite stable during follow-up. The physical component deterio-
ated after surgery and remained quite stable throughout the
hole year of follow-up, without differences between SLNB and
LND groups. In previous studies by Purushotham et al. [36] and
el Bianco et al. 37], no significant differences between these
reatments were found either.
Previous studies showed QOL differences depending on ed-
cation level [38,39]. In our study, women with primary school
resented lower (worse) QOL scores than did those with second-
ry or university studies at baseline. This difference between
ducation level groups, however, disappeared after surgery and
hereafter. This finding could reflect the universal coverage of
he Spanish National Health Service, which facilitates access to
reventive and treatment services independently of socioeco-
omic status.
In summary, our findings support that general well-being
cales do not reflect the impact of upper limbmorbidity on QOL of
atients with breast cancer. To assess the effect of SLNB versus
LND in QOL, proper questionnaires also covering the treatment
mpact on the arm are needed. On the other hand, it is not surpris-
ng that scales such as physical functioning do not cover this as-
ect because their focus is on limitations of lower limb mobility
whatever the questionnaire used). However, this is not the case
or social or emotional scales whose content is not directly related
o physical limitation but rather to the impact on mental health
nd participation in society. Therefore, these negative results
ight be suggesting that upper arm morbidity has no real impact
n emotional and social well-being.
Some limitations of this study should be taken into account.
irst, this is an observational study and participants were not ran-
omly assigned to treatment groups. ALND was applied to all pa-
ients with positive nodes, and the clinical stage itself could be a
reat impact in the prognosis and QOL for a patient with breast
ancer. However, currently, the indication of the SLNB technique
s well demonstrated and a clinical trial would not be justified in
his case. To take possible effects of clinical differences into ac-ount, T and N were included in the generalized estimation equa-
ionmodels, whichwere also adjusted by other relevant variables.
econd, the samplewas smaller than forecasted due to 13 patients
ho refused to continue in the study before surgery, which led to
final sample of 93. It was, however, partly compensated by loss of
ollow-up, which was lower than 20% assumed in the sample size
alculation (14%). Furthermore, the reasons why patients dropped
ut during follow-up (nine SLNB and four ALND) were not disease-
elated, according to the review of medical records. On the other
and, we consider that the strengths of our study were the longi-
udinal prospective design, which included preoperative baseline
ssessment, and that we used validated generic and disease-spe-
ific QOL questionnaires, the SF-36 and the FACT-B4, thus allow-
ng comparison with relevant previous studies to clarify the sub-
equent reasons for controversy.
Conclusion
In conclusion these results confirm that SLNB is associated with
better patient well-being in comparison to ALND. Disagreement
between previous QOL studies comparing SLNB and ALND is ex-
plained by differences in the instruments used to measure QOL.
Our findings confirm that there are clinically relevant between-
treatment differences in Arm functioning and upper limbmorbid-
ity, while there are no relevant differences in general well-being at
this time frame, measured with disease-specific questionnaires
such as the FACT-B4 or generic questionnaires such as the SF-36.
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